Speech-Language Pathologists in Norfork, AR Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Growing Speech Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8020 Push Mountain Rd, Norfork, AR 72658 Phone: 870-405-9366 |
 Reta Light, MCD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 161 Mildred Simpson Dr, Norfork, AR 72658 Phone: 870-499-7192 Fax: 870-499-7196 |
News Archive
Scientists reveal first comprehensive genomic analysis of aggressive lymphomas
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
AARP and coalition group urge Governor to enact legislation
Legislation that will bring a sweeping reform to the way in which for-profit nursing homes operate in Illinois and that will greatly improve the quality of care and safety for institutionalized residents passed the State Senate today, and is on its way to the Governor's desk.
Predators in the scientific world plaguing research work finds major investigation
According to new research that looks at the research world itself, there is a huge percentage of journals that are publishing thousands of research papers of little value and poor quality. The results from this investigation were published yesterday, 7th September 2017 in the journal Nature in a study entitled, "Stop this waste of people, animals and money".
Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH
Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.
› Verified 2 days ago